Hemostemix Inc (HEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hemostemix Inc (HEM) has a cash flow conversion efficiency ratio of 0.839x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-2.91 Million ≈ $-2.10 Million USD) by net assets (CA$-3.46 Million ≈ $-2.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hemostemix Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Hemostemix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Hemostemix Inc for a breakdown of total debt and financial obligations.
Hemostemix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hemostemix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Garovaglio y Zorraquin S.A.
BA:GARO
|
-0.041x |
|
Inter-Delta Tbk
JK:INTD
|
-0.225x |
|
Oceancash Pacific Bhd
KLSE:0049
|
-0.012x |
|
Avalon Holdings Corporation
NYSE MKT:AWX
|
0.039x |
|
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
|
-0.015x |
|
LabGenomics Co. Ltd
KQ:084650
|
-0.034x |
|
Axiom Properties Ltd
AU:AXI
|
-0.145x |
|
Pharmacielo Ltd
V:PCLO
|
0.236x |
Annual Cash Flow Conversion Efficiency for Hemostemix Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Hemostemix Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Hemostemix Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-7.20 Million ≈ $-5.21 Million |
CA$-1.90 Million ≈ $-1.38 Million |
0.264x | +29.94% |
| 2023-12-31 | CA$-7.37 Million ≈ $-5.33 Million |
CA$-1.50 Million ≈ $-1.08 Million |
0.203x | -77.46% |
| 2022-12-31 | CA$-6.77 Million ≈ $-4.90 Million |
CA$-6.10 Million ≈ $-4.41 Million |
0.901x | +36.96% |
| 2021-12-31 | CA$-5.28 Million ≈ $-3.82 Million |
CA$-3.48 Million ≈ $-2.52 Million |
0.658x | -87.90% |
| 2020-12-31 | CA$-1.10 Million ≈ $-794.78K |
CA$-5.98 Million ≈ $-4.32 Million |
5.438x | +546.31% |
| 2019-12-31 | CA$-4.05 Million ≈ $-2.93 Million |
CA$-3.40 Million ≈ $-2.46 Million |
0.841x | +115.26% |
| 2018-12-31 | CA$487.80K ≈ $352.87K |
CA$-2.69 Million ≈ $-1.95 Million |
-5.513x | -730.03% |
| 2017-12-31 | CA$4.84 Million ≈ $3.50 Million |
CA$-3.21 Million ≈ $-2.32 Million |
-0.664x | -185.48% |
| 2016-12-31 | CA$-3.46 Million ≈ $-2.50 Million |
CA$-2.69 Million ≈ $-1.95 Million |
0.777x | +103.82% |
| 2015-12-31 | CA$174.08K ≈ $125.93K |
CA$-3.55 Million ≈ $-2.56 Million |
-20.365x | -2102.29% |
| 2014-12-31 | CA$3.39 Million ≈ $2.45 Million |
CA$-3.13 Million ≈ $-2.27 Million |
-0.925x | +52.07% |
| 2013-12-31 | CA$573.87K ≈ $415.13K |
CA$-1.11 Million ≈ $-800.95K |
-1.929x | -- |
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more